Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results

Theravance Biopharma (NASDAQ:TBPH) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25), Yahoo Finance reports. The company had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $15.81 million. Theravance Biopharma had a negative return on equity of 18.97% and a negative net margin of 72.79%. During the same period in the prior year, the business posted ($0.28) EPS.

Theravance Biopharma Trading Down 0.1 %

TBPH traded down $0.01 on Wednesday, reaching $7.82. The stock had a trading volume of 3,710,698 shares, compared to its average volume of 410,428. The business’s 50-day moving average price is $9.05 and its two-hundred day moving average price is $9.09. Theravance Biopharma has a 12-month low of $7.69 and a 12-month high of $11.71. The company has a market cap of $380.31 million, a P/E ratio of -9.22 and a beta of 0.24.

Insider Activity

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now owns 335,965 shares in the company, valued at $3,023,685. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TBPH. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright decreased their target price on Theravance Biopharma from $20.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday. TD Cowen cut their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, SVB Leerink lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $15.00 to $10.00 in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.